Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer

Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. Observations: A 68-year-old man...

Full description

Bibliographic Details
Main Authors: Matthew G. Field, H. Culver Boldt, Taher Abu Hejleh, Elaine M. Binkley
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:American Journal of Ophthalmology Case Reports
Subjects:
Choroidal metastasis
Epidermal growth factor receptor
EGFR
Lung adenocarcinoma
Osimertinib
Tyrosine kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2451993622002055

Internet

http://www.sciencedirect.com/science/article/pii/S2451993622002055

Similar Items